 Kezar Life Sciences Inc NASDAQ: KZR shares are trading lower by 38.23 at 7.61 after the company announced top-line results from its PRESIDIO Phase 2 clinical trial of Zetomipzomib. Kezar Life Sciences says most patients saw clinically meaningful improvements in the primary endpoint measure of. 